Ultragenyx Pharmaceutical RARE Product — Sales Reserves Provisions
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:SalesReservesProvisions.
The official record: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's product — sales reserves provisions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's product — sales reserves provisions?
- Ultragenyx Pharmaceutical (RARE) reported product — sales reserves provisions of $12.5M in Q4 2025.
- How has Ultragenyx Pharmaceutical's product — sales reserves provisions changed year-over-year?
- Ultragenyx Pharmaceutical's product — sales reserves provisions increased by 31.6% year-over-year, from $9.5M to $12.5M.
- What is the long-term trend for Ultragenyx Pharmaceutical's product — sales reserves provisions?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's product — sales reserves provisions has grown at a 51.1% compound annual growth rate (CAGR), from $9.59M to $50M.
- What does product — sales reserves provisions mean?
- This metric captures the periodic expense recognized to increase the sales reserve balance, reflecting anticipated future deductions from gross revenue. It is a critical indicator of the expected impact of contractual rebates, chargebacks, and other price concessions on net revenue. High provisions relative to revenue may signal increased pricing pressure or competitive discounting.